Amedeo's Top 20

Amedeo Smart

Independent Medical Education


22 October 2018

Multidisciplinary Journal Club

  1. Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, et al.
    Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.
    N Engl J Med 2018;379:1431-1442.

  1. Mehta MP, Kotecha R.
    Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?
    J Clin Oncol 2018.

  2. Borducchi EN, Liu J, Nkolola JP, Cadena AM, et al.
    Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.
    Nature 2018.

  3. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, et al.
    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    N Engl J Med 2018.

  4. Park H, Wang W, Henry L, Nelson DR, et al.
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology 2018.

  1. O'Brien TR, Yang HI, Groover S, Jeng WJ, et al.
    Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.
    Gastroenterology 2018.

  2. Nardelli S, Gioia S, Ridola L, Farcomeni A, et al.
    Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology 2018.

  3. Muftuoglu M, Olson A, Marin D, Ahmed S, et al.
    Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy.
    N Engl J Med 2018;379:1443-1451.

  4. Roul H, Mary-Krause M, Ghosn J, Delaugerre C, et al.
    CD4 cell count recovery after combined antiretroviral therapy in the modern cART era.
    AIDS 2018.

  5. Lockmer S, Ostenstad B, Hagberg H, Holte H, et al.
    Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
    J Clin Oncol 2018.

  1. McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, et al.
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol 2018.

  2. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, et al.
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med 2018.

  3. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, et al.
    Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.
    Clin Infect Dis 2018.

  4. Laut KG, Shepherd L, Gottfredsson M, Sedlacek D, et al.
    Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations.
    AIDS 2018.

  5. Grani G, Lamartina L, Ascoli V, Bosco D, et al.
    Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the "right" TIRADS.
    J Clin Endocrinol Metab 2018.

  1. Slutsker JS, Hennessy RR, Schillinger JA.
    Factors Contributing to Congenital Syphilis Cases - New York City, 2010-2016.
    MMWR Morb Mortal Wkly Rep 2018;67:1088-1093.

  2. Iesari S, Ackenine K, Foguenne M, De Reyck C, et al.
    Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial.
    Ann Surg 2018;268:776-783.

  3. Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, et al.
    Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Ann Surg 2018.

  4. Huntington SF, von Keudell G, Davidoff AJ, Gross CP, et al.
    Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    J Clin Oncol 2018.

  5. Frias JP, Nauck MA, Van J, Kutner ME, et al.
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet 2018.


more..


Privacy Policy